Guggenheim Raises Price Target for Praxis Precision Medicines (PRAX)

Praxis Precision Medicines (NASDAQ:PRAX) is 1 of the 17 biotechnology stocks with much than 50% upside.

On February 10, Guggenheim expert Yatin Suneja raised the terms people connected Praxis Precision Medicines (NASDAQ:PRAX) from $760 to $800. He maintained a Buy standing connected the stock, which helium believes offers much than 140% upside.

Sergey Nivens/Shutterstock.com

Suneja highlighted his investigation and feedback from manufacture experts, which suggests ulixacaltamide’s marketplace adoption imaginable successful indispensable tremor, supporting a marketplace accidental supra $15 cardinal and projecting highest income of $5-$10 billion. Praxis Precision Medicines (NASDAQ:PRAX) besides maintained its presumption of being among Guggenheim’s Top Picks for 2026.

Back connected January 30, the terms people connected Praxis Precision Medicines (NASDAQ:PRAX) was raised from $340 to $1,245 by H.C. Wainwright expert Douglas Tsao arsenic well. The expert assigned a Buy standing to the banal with revised upside imaginable of 274%.

Tsao believes that ulixacaltamide has proven to beryllium “transformative” for the company. At the aforesaid time, relutrigine is presently being ignored but volition yet thrust “significant value” successful the stock. He accrued his highest income predictions for some ulixacaltamide and relutrigine. Notably, his outlook for relutrigine is overmuch much optimistic, with expected highest income reaching $6.8 billion.

Praxis Precision Medicines (NASDAQ:PRAX) is progressive successful processing therapies to cure disorders related to the cardinal tense system, which are characterized by neuronal excitation-inhibition imbalance. These disorders see epilepsy, question disorders, and depression. The institution utilizes its proprietary platforms similar Cerebrum and Solidus to people specified imbalances.

While we admit the imaginable of PRAX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.